Home > Insider Trading > Filing (0001567619-21-003193)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1601485	Angion Biomedica Corp.	ANGN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1413350	Jay Venkatesan	C/O Angion Biomedica Corp. 51 Charles Lindbergh Blvd. Uniondale NY 11553	See Remarks	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-02-09	31,966	$16.00	1,037,017	No	4	F	Direct
Common Stock	Acquisiton	2021-02-09	165,094	$0.00	1,202,111	No	4	C	Direct
Common Stock	Acquisiton	2021-02-09	237,152	$6.43	1,439,263	No	4	X	Direct
Common Stock	Disposition	2021-02-09	159,177	$16.00	1,208,086	No	4	S	Direct
Common Stock	Acquisiton	2021-02-09	262	$11.57	1,280,348	No	4	C	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	C	Direct
No	4	X	Direct
No	4	S	Direct
No	4	C	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Cumulative Convertible Preferred	Disposition	2021-02-09	1,804	$0.00	1,804	$0.00
Common Stock	Warrant to Purchase Common Stock	Disposition	2021-02-09	237,152	$0.00	237,152	$6.43
Common Stock	Convertible Promissory Note	Disposition	2021-02-09	0	$0.00	0	$16.00

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
	No	4	C	Direct
2028-07-05	No	4	X	Direct
	No	4	C	Direct

Footnotes

The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs").
Includes 246,299 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
Each share of the issuer's Series C Preferred Stock automatically converted into 91.52 shares of the issuer's Common Stock immediately prior to the consummation of the issuer's IPO and had no expiration date.
On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,328 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's IPO price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's IPO, the Issuer withheld 159,177 of the warrant shares to pay the exercise price and issued the remaining 237,152 shares of common stock to Reporting Person.
The convertible promissory note converted immediately prior to the consummation of the IPO into Common Stock.
The convertible promissory note ("Convertible Note") had a maturity date of August 14, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share.